• DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

DNDi and Fiocruz sign partnership to find new treatments for dengue

Representatives of the two institutions also signed a strategic alliance for neglected diseases and announced the joint submission of the project to the Brazilian funding agency, Finep

Home > News

DNDi and Fiocruz sign partnership to find new treatments for dengue

Representatives of the two institutions also signed a strategic alliance for neglected diseases and announced the joint submission of the project to the Brazilian funding agency, Finep

Fiocruz and DNDi representatives
Rio de Janeiro — 4 Apr 2022
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print
  • English
    • English
    • Español
    • Português

The Drugs for Neglected Diseases initiative (DNDi) and the Oswaldo Cruz Foundation (Fiocruz) have signed a memorandum of understanding for research and treatment of dengue. The two institutions also sealed a strategic research alliance and submitted a joint project to the Finep Public Notice for Neglected Diseases. 

At the meeting, DNDi’s global Director of Research and Development, Laurent Fraisse, the President and Chair of the Board of Directors of DNDi Latin America, Michel Lotrowska, and DNDi’s Regional Executive Director in Latin America, Sergio Sosa-Estani, were received by the President of Fiocruz, Nísia Trindade Lima, who praised the historic cooperation between the two institutions. 

‘Formalizing this alliance is important not only for the memorandum of understanding, but also because it consolidates a whole path of common projects and will allow us to develop a strategic plan for the future, focused on neglected diseases and neglected populations,’ Nísia said. 

Nísia Trindade Lima, President of Fiocruz, and Laurent Fraisse, R&D Director at DNDi

In his address to the meeting, Laurent Fraisse also celebrated the advances. ‘We have the desire to prioritize our best partners. With Fiocruz, this was the case before, it is today, and it will be for the future. We want to bring our energy to contribute alongside the skill and capacity of this institution and elevate the partnership to a strategic level.’ Fraisse also recalled the meetings he had with Fiocruz Vice Presidents Rodrigo Correa (Research and Biological Collections) and Marco Krieger (Production and Innovation in Health). ‘There were very productive conversations about diseases such as Chagas disease and leishmaniasis. And we have advanced in discussing our plans for research to tackle dengue, a new DNDi project,’ he said. 

Partnership on dengue 

Collaboration between Fiocruz and DNDi on dengue will form part of a wider global research and development partnership to find a treatment for the disease, led by DNDi with partner institutions in India, Thailand, and Malaysia. The organization is also planning to join with institutions from African countries, such as the Democratic Republic of the Congo and Ghana, to conduct epidemiological studies. Fiocruz plays a central role in this network because of the wide range of its activities. 

The number of dengue incident cases worldwide increased by 85% from 1990 to 2019. This rate is expected to rise due to the increasing temperatures related to climate change, potentially reaching 60% of the world’s population by 2080. The search for a comprehensive approach to addressing dengue should also include diagnosis and vaccines. 

The Vice President of Health Production and Innovation, Marco Krieger, praised this new front of action. ‘We were promoting this initiative even before the pandemic. It adds to projects we already had, such as for Chagas disease, leishmaniasis, and malaria – which all impact people living in the Latin American region.’ 

Strategic alliance 

A strategic alliance between DNDi and Fiocruz has also been formalized. The goal is to strengthen the existing relationship by establishing a Joint Strategic Committee to oversee all current and future collaborations, which take place across numerous areas of research and development, and across advocacy and treatment access programmes for multiple infectious diseases. By 2028, the two institutions hope to help strengthen capacities in the Latin American region and ensure that new safe, effective, and accessible drugs are developed and delivered to neglected patients. The next steps involve the creation of a working group to define the structure and governance of the Joint Strategic Committee and identify potential areas of collaboration in pharmaceutical research and development, implementation research, and pharmaceutical production for Chagas, leishmaniasis, hepatitis C, dengue, and paediatric HIV. 

Vice President of Research and Biological Collections, Rodrigo Correa, said there is much to gain from the exchange of information and experiences. ‘DNDi is interested in using Fiocruz’s network of biobanks,’ he said. ‘We hope to continue to expand this partnership.’ Jorge Mendonça, Director of the Institute of Drug Technology (Farmanguinhos/Fiocruz), also revealed that there is the potential to bring a treatment for hepatitis C to Brazil through its partnership with DNDi. ‘The next step is to present the documentation to Anvisa [the National Health Surveillance Agency].’  He said that the alliance will also allow for the strategic optimization of diagnosis and treatment: ‘Reducing the time between diagnosis and treatment will be very important for the health system.’ 

The alliance will also collaborate on the advocacy front, as highlighted by Sergio Sosa Estani, Regional Executive Director of DNDi in Latin America. ‘To be able to develop action plans, we need an enabling environment for strong partnerships,’ he explained. ‘Optimizing this environment requires specific advocacy to bring us closer to key actors.’ 

Projects for neglected diseases 

DNDi and Fiocruz submitted a joint project to Finep’s call for research promotion, development, and innovation for neglected, tropical, and vector-borne diseases, among other diseases. The project Accelerating the preclinical and clinical development of treatments for dengue by repurposing drugs aims to lay the pre-clinical and translational foundations required to begin the clinical evaluation of repurposed drugs intended for early use, which can prevent the onset and/or reduce the duration of symptoms and prevent progression to the severe form of the disease. 

The joint project will seek to validate and select at least one clinical candidate (ideally a combination of an antiviral agent and an anti-inflammatory or antiplatelet agent) and prepare the regulatory steps required to initiate a Phase II clinical study in Brazil, aiming for successful clinical development and approval of a new treatment for dengue. 

Written in collaboration with Ciro Oiticica, Agência Fiocruz

Partnership Dengue Brazil

Read, watch, share

Loading...
Woman standing in front of a house
Press releases
2 Feb 2023

Dutch government renews support to DNDi projects on poverty-related diseases that disproportionately impact women

Statements
1 Feb 2023

DNDi interventions at the 152nd session of the WHO Executive Board

Young man sitting in hospital setting
News
25 Jan 2023

It’s time medical innovation reached the 1.7 billion people affected by neglected tropical diseases: World NTD Day 2023

Film Poster Voices of Leishmaniasis: Shushi from India
Videos
25 Jan 2023

Voices of leishmaniasis: Shishu from India

Child receiving treatment
News
20 Jan 2023

DNDi’s 20th year of bringing the best science for the most neglected

Child affected by dengue and her mother at their home in Bangkok, Thailand.
Stories
16 Dec 2022

2022: Six advances in neglected disease research to remember

Statements
2 Dec 2022

DNDi‘s comments on the conceptual zero draft for the consideration of the Intergovernmental Negotiating Body at INB3

Healthcare workers discussing in hospital setting
Press releases
1 Dec 2022

DNDi partners in a new NIHR-funded Global Health Research Group on HIV-associated Fungal Infections (IMPRINT)

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo